Konsolidace léčby melfalanem 100 mg/m2 s novými léky pro pacienty s mnohočetným myelomem v náhlé progresi

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F10%3A00040738" target="_blank" >RIV/00216224:14110/10:00040738 - isvavai.cz</a>

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Konsolidace léčby melfalanem 100 mg/m2 s novými léky pro pacienty s mnohočetným myelomem v náhlé progresi

Original language description

Patients with fulminant progression of multiple myeloma after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan followed by PBSC support and consolidation therapy using regimens containing thalidomide or bortezomib.Treatment with upfront MEL 100 followedby a thalidomide or bortezomibbased regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Annals of hematology

ISSN

0939-5555

e-ISSN

—

Volume of the periodical

89

Issue of the periodical within the volume

5

Country of publishing house

DE - GERMANY

Number of pages

5

Pages from-to

—

UT code for WoS article

000275709100007

EID of the result in the Scopus database

—